Clinical Trial on Chronic Insomnia and Sleep Architecture

Journal Context: European Neurology | Identifiers: DOI: 10.1159/000115897 / PMID: 6747620

Principal Investigators: Schneider-Helmert, D., & Schoenenberger, G. A. (Medical Center Mariastein / Research Division, Department of Surgery, University of Basel, Switzerland)

Methodology: A randomised, double-blind, placebo-controlled human study evaluating 14 chronic insomniac patients. Subjects received daily intravenous infusions of DSIP ($30\ \text{nmol/kg}$) or a matching saline placebo over a multi-day testing protocol. Real-time sleep metrics were recorded via continuous polysomnography (PSG) to track sleep stages, while daytime psychomotor tests evaluated cognitive clarity.

Key Findings: DSIP administration resulted in a profound, natural optimization of sleep architecture. Treated subjects experienced a statistically significant increase in total sleep time, a targeted expansion of slow-wave sleep (Delta sleep), and an absolute reduction in sleep latency (falling asleep faster). Crucially, unlike traditional sedatives, DSIP completely eliminated morning grogginess, instead generating a marked increase in daytime alertness, focus, and psychological performance scores, confirming its status as a physiological sleep modulator.